leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.
(
CSE:AGNOTCQB:AGNPF
)

Algernon announces 25% enrollment for its Phase 2 idiopathic pulmonary fibrosis and chronic cough study of Ifenprodil

The purpose of the open-label, proof-of-concept Phase 2 human trial of 20 patients is to determine the efficacy of Ifenprodil to preserve lung function

lung
There are five sites in total participating in the study with three located in Australia and two in New Zealand

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCB:BTHCF) (FRA:AGW) announced that it has reached 25% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil).

“I am very pleased to report that we have reached 25% enrollment in the study,” said CEO Christopher J. Moreau in a statement.

“While our COVID-19 clinical trial program has received a great deal of attention, IPF and chronic cough are very serious conditions as well, and our team is working hard to make sure our clinical program of investigating Ifenprodil as a possible treatment continues to move forward on schedule.”

READ: Algernon Pharmaceuticals names Dr Mark Swaim to its medical and scientific advisory board

Vancouver-based Algernon said the purpose of the open-label, proof-of-concept Phase 2 human trial of 20 patients is to determine the efficacy of Ifenprodil in the preservation of lung function in IPF patients (including biomarkers of fibrosis) and its associated cough. 

There are five sites in total participating in the study with three located in Australia and two in New Zealand.

Ifenprodil has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of (IPF). In addition, Ifenprodil significantly reduced both cough frequency and onset in a guinea pig acute cough model.

The drug is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil prevents glutamate signaling. The NMDA receptor is found on many tissues including lung cells, T-cells, and neutrophils.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

 

 

Quick facts: Algernon Pharmaceuticals Inc.

Follow
CSE:AGN

Price: 0.095 CAD

Market Cap: $15.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon looks for IND meeting with FDA for Ifenprodil study on chronic...

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has plans to file a pre-IND meeting request with the U.S. Food and Drug Administration for an Ifenprodil Phase 2 chronic cough study. Moreau telling Proactive, they have decided to...

1 day, 15 hours ago

2 min read